Abrams RA, Winter KA, Safran H, et al. - Researchers designed NRG/RTOG 0848 with the aim to ascertain if survival following gemcitabine-based adjuvant chemotherapy could be improved with adjuvant radiation with fluoropyrimidine sensitization in patients with resected pancreatic head adenocarcinoma. In step 1 of this protocol, randomization of patients to either adjuvant gemcitabine or the combination of gemcitabine and erlotinib was done. In this manuscript, they reported the final analysis of these step 1 data. Eligibility criteria were—within 10 weeks of curative intent pancreaticoduodenectomy with postoperative CA19-9 < 180. In gemcitabine arm, 6 cycles of gemcitabine were provided. Gemcitabine+erlotinib arm received gemcitabine and erlotinib 100 mg/d. One hundred and sixty-three patients were randomized and were evaluable in arm 1 and 159 in arm 2. Outcomes provide no evidence for increased OS in this trial in correlation with The addition of adjuvant erlotinib to gemcitabine.